Sareum Share News (SAR)

Sareum Information

Buy SAR Shares
Add SAR to Watchlist
Add SAR to Alert

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 36.00

Bid: 35.00

Ask: 37.00

Change: 2.50 (7.46%)

Spread: 2.00 (5.714%)

Open: 33.50

High: 36.00

Low: 33.00

Prev. Close: 33.50

Last checked at -

Small caps round-up: YouGov, Sareum and InterQuest...

Tue, 07th Aug 2012 11:25

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Forming Plastic and Articles Made Therefrom', has been granted by the US Patent Office. This is ERT's core patent in the US for the PIM process. Sareum, a specialist cancer drug discovery business, has said it notes the recent significant rise in its share price and has confirmed that "advanced stages of negotiations are taking place with a potential licencing partner". It added these "may or may not lead to a licencing agreement regarding one of the company's research programmes". Shares were up 184% on Tuesday, equal to 1.15p. The stock has gained 42% over the past year, and 163% in the past month. YouGov, the online market research firm, is anticipating that its operating profit will be in line with expectations with second half revenue similar to that achieved in the first half, reflecting the firm's focus on profitability in the German business and the expected end to a long-term contract in Iraq. The firm said its balance sheet remains strong with cash at July 31st of around £7.0m. TClarke, a building services company, reported a decline in pre-tax profit for the half year at £0.5m (2011: £1.4m) on revenues of £90.7m (2011: £92.6m), with the profit margin also lower at 0.5% compared to 1.5% the previous year. Basic earnings per share dropped from 2.38p to 0.79p, while net cash climbed £0.1m to £0.7m. The interim dividend was maintained at 1p per share. The firm blamed a lack of confidence across the sector for the declines and said that with a number of projects due to begin shortly it is confident of significant revenue progress in the second half. Shares in InterQuest Group, a specialist information technology recruitment group, took a hit after it admitted earnings before interest, tax, depreciation and amortisation are expected to be down year-on-year, in the region of £1.15m (2011: £1.86m), and warned the impact of investments and restructuring on profitability for 2012 will be around £1.6m. Trading conditions were poor in both the UK and Far East, particularly in the second quarter and particularly in the banking and finance sectors from which it derives 27% of its net fee income. This has meant profitability from investments has taken longer than anticipated. NR

More News

7 Dec 2023 14:31

UK shareholder meetings calendar - next 7 days

Friday 8 December
Amedeo Air Four Plus Ltd	AGM
Ashoka India Equity Investment Trust PLC	AGM
Associated British Engineering PLC	AGM
Associated British Foods PLC	AGM
Corcel PLC	GM re disposal of 41% interest in the Mambare nickel/cobalt project
Hargreaves Lansdown PLC	AGM
URA Holdings PLC	GM re closing the fundraise
Monday 11 December
IamFire PLC	AGM with vote on name change to WeCap PLC
Pharma C Investments PLC	GM re allowing investments in fintech, AI sectors
SigmaRoc PLC	GM re reverse takeover
Tribal Group PLC	GM re cash offer by Tiger Bidco 1 Ltd
Vela Technologies PLC	AGM
Tuesday 12 December
Atalaya Mining PLC	EGM re redomiciliation to Spain from Cyprus
Blackrock Greater Europe Investment Trust PLC	AGM
Distil PLC	GM re placing and subscription
Gelion PLC	AGM
Wednesday 13 December
Dechra Pharmaceuticals PLC	AGM
Limitless Earth PLC	AGM
Softcat PLC	AGM
Volution Group PLC	AGM
Thursday 14 December
Aeorema Communications PLC	AGM
CleanTech Lithium PLC	GM re equity raise approval
Driver Group PLC	Full Year Results
eEnergy Group PLC	AGM
Ethernity Networks Ltd	GM re authority to allot shares on non-preemptive basis
Fintech Asia Ltd	AGM
Helium One Global Ltd	AGM
Marwyn Value Investors Ltd	AGM
Quarto Group Inc	GM re cancelling trading on London's Main Market
Sareum Holdings PLC	AGM

Copyright 2023 Alliance News Ltd. All Rights Reserved.

23 Nov 2023 14:28

IN BRIEF: Sareum Holdings draws down on equity prepayment facility

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the GBP300,000 second deposit in respect of a previously announced equity prepayment facility.

9 Nov 2023 13:47

EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

3 Nov 2023 13:59

Sareum secures Japan patent for kinase inhibitor asset

(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.

3 Nov 2023 09:01

Sareum says patent notice in Japan boosts confidence in SDC-1801

(Alliance News) - Sareum Holdings PLC on Friday said it received a notice of allowance from Japan's Patent Office for a patent relating to its lead TYK2/JAK1 kinase inhibitor, SDC-1801.

9 Oct 2023 15:06

Sareum losses widen as clinical trials continue

(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.

9 Oct 2023 10:58

Sareum says earnings down but product development going well

(Alliance News) - Sareum Holdings PLC on Monday said its annual loss widened and its cash reserves are substantially reduced, but that development and testing of its medicinal products is progressing well.

6 Sep 2023 14:35

Director dealings: Blackbird, Sareum insiders pick up shares

(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.

4 Sep 2023 09:18

Sareum begins dosing participants in phase 1a trial for SDC-1801

(Alliance News) - Sareum Holdings PLC on Monday said it has successfully started the multiple ascending dose part of its phase 1a clinical trial for its SDC-1801 drug, following approval from the safety review committee.

16 Aug 2023 13:13

Sareum flagship drug trial progressing well ahead of annual results

(Alliance News) - Sareum Holdings PLC on Wednesday said a clinical trial for its main therapeutic is continuing as planned, and it hopes to use a new prepayment facility to further enhance development.

3 Aug 2023 14:16

IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs.

26 Jun 2023 17:33

TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News:

26 Jun 2023 10:54

Sareum granted new patents in China, US

(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.

6 Jun 2023 13:36

IN BRIEF: Sareum doses first subjects in psoriasis drug trial

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results.

18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Latest Share Chat

Sareum Share News (SAR)

Share Price Information for Sareum (SAR)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: YouGov, Sareum and InterQuest...

Login to your account

Quickpicks are a member only feature

Login to your account